{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:19:43Z","timestamp":1775143183166,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.chest.2023.10.023","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T01:55:53Z","timestamp":1698458153000},"page":"810-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ozanimod Therapy in Patients With COVID-19 Requiring Oxygen Support"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6402-7953","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lellouche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Blais-Lecours","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-4651","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Maltais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuyen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Ch\u00e2teauvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Marsolais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2023.10.023_bib1","unstructured":"World Health Organization. Therapeutics and COVID-19: living guideline. Accessed September 16, 2022. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.4"},{"issue":"10223","key":"10.1016\/j.chest.2023.10.023_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"10234","key":"10.1016\/j.chest.2023.10.023_bib3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.chest.2023.10.023_bib4","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2002-06-1887","article-title":"The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome","volume":"101","author":"Aird","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.chest.2023.10.023_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrd2356","article-title":"Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules","volume":"8","author":"Marsolais","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.chest.2023.10.023_bib6","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013424","article-title":"Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19","volume":"13","author":"Marfia","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"16","key":"10.1016\/j.chest.2023.10.023_bib7","doi-asserted-by":"crossref","first-page":"9308","DOI":"10.1016\/S0021-9258(19)38849-0","article-title":"An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors","volume":"265","author":"Hla","year":"1990","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.chest.2023.10.023_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nchembio.547","article-title":"Actions of a picomolar short-acting S1P(1) agonist in S1P(1)-eGFP knock-in mice","volume":"7","author":"Cahalan","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1016\/j.chest.2023.10.023_bib9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.cell.2011.08.015","article-title":"Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection","volume":"146","author":"Teijaro","year":"2011","journal-title":"Cell"},{"issue":"29","key":"10.1016\/j.chest.2023.10.023_bib10","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1073\/pnas.1107024108","article-title":"Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.chest.2023.10.023_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.trsl.2008.09.002","article-title":"Sphingosine 1-phosphate rescues canine LPS-induced acute lung injury and alters systemic inflammatory cytokine production in\u00a0vivo","volume":"152","author":"Szczepaniak","year":"2008","journal-title":"Transl Res"},{"issue":"3","key":"10.1016\/j.chest.2023.10.023_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1124\/mol.108.048769","article-title":"Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza","volume":"74","author":"Marsolais","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.chest.2023.10.023_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/fcp.12284","article-title":"Fingolimod (Gilenya\u00ae) in multiple sclerosis: bradycardia, atrioventricular blocks, and mild effect on the QTc interval. Something to do with the L-type calcium channel?","volume":"31","author":"Pilote","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.chest.2023.10.023_bib14","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.bmcl.2004.04.070","article-title":"Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists","volume":"14","author":"Hale","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.chest.2023.10.023_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpdd.383","article-title":"Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT\/QTc study","volume":"7","author":"Tran","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10.1016\/j.chest.2023.10.023_bib16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.chest.2023.10.023_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.chest.2023.10.023_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.chest.2023.10.023_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.795574","article-title":"Risk for cardiovascular adverse events associated with sphingosine-1-phosphate receptor modulators in patients with multiple sclerosis: insights from a pooled analysis of 15 randomised controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.chest.2023.10.023_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/cer-2019-0169","article-title":"Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis","volume":"9","author":"Swallow","year":"2020","journal-title":"J\u00a0Comp Eff Res"},{"issue":"1","key":"10.1016\/j.chest.2023.10.023_bib21","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"Axfors","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.chest.2023.10.023_bib22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1177\/0962280215588241","article-title":"Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable","volume":"25","author":"Whitehead","year":"2016","journal-title":"Stat Methods Med Res"},{"issue":"10236","key":"10.1016\/j.chest.2023.10.023_bib23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.chest.2023.10.023_bib24","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \"sepsis-related problems\" of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2023.10.023_bib25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1378\/chest.07-0617","article-title":"Comparison of the SpO2\/FIO2 ratio and the PaO2\/FIO2 ratio in patients with acute lung injury or ARDS","volume":"132","author":"Rice","year":"2007","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.chest.2023.10.023_bib26","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2023.10.023_bib27","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1212\/NXI.0000000000000839","article-title":"Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS","volume":"7","author":"Harris","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.chest.2023.10.023_bib28","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.chest.2021.01.009","article-title":"Effect of ultrashort-acting beta-blockers on mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a systematic review and meta-analysis of randomized controlled trials","volume":"159","author":"Hasegawa","year":"2021","journal-title":"Chest"},{"issue":"16","key":"10.1016\/j.chest.2023.10.023_bib29","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.2013.278477","article-title":"Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial","volume":"310","author":"Morelli","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.chest.2023.10.023_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1039","article-title":"The effect of fingolimod on patients with moderate to severe COVID-19","volume":"11","author":"Teymouri","year":"2023","journal-title":"Pharmacol Res Perspect"},{"issue":"14","key":"10.1016\/j.chest.2023.10.023_bib31","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1074\/jbc.M311743200","article-title":"Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate","volume":"279","author":"Sanna","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.chest.2023.10.023_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results","volume":"12","author":"Cohen","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"10.1016\/j.chest.2023.10.023_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2023.10.023_bib34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223056684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223056684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T14:51:45Z","timestamp":1729090305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223056684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0012369223056684"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.10.023","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ozanimod Therapy in Patients With COVID-19 Requiring Oxygen Support","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}